Logo image of IMNN

IMUNON INC (IMNN) Stock Fundamental Analysis

NASDAQ:IMNN - Nasdaq - US15117N6022 - Common Stock

0.8965  -0.02 (-1.82%)

Premarket: 0.8851 -0.01 (-1.27%)

Fundamental Rating

2

Overall IMNN gets a fundamental rating of 2 out of 10. We evaluated IMNN against 572 industry peers in the Biotechnology industry. IMNN scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. IMNN has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

IMNN had negative earnings in the past year.
In the past year IMNN has reported a negative cash flow from operations.
IMNN had negative earnings in each of the past 5 years.
In the past 5 years IMNN always reported negative operating cash flow.
IMNN Yearly Net Income VS EBIT VS OCF VS FCFIMNN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 -10M -20M -30M

1.2 Ratios

Looking at the Return On Assets, with a value of -186.58%, IMNN is doing worse than 89.56% of the companies in the same industry.
IMNN has a worse Return On Equity (-483.32%) than 80.18% of its industry peers.
Industry RankSector Rank
ROA -186.58%
ROE -483.32%
ROIC N/A
ROA(3y)-66.24%
ROA(5y)-59.99%
ROE(3y)-101.8%
ROE(5y)-107.31%
ROIC(3y)N/A
ROIC(5y)N/A
IMNN Yearly ROA, ROE, ROICIMNN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 -100 -200 -300

1.3 Margins

IMNN does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
IMNN Yearly Profit, Operating, Gross MarginsIMNN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 -2K -4K -6K

More info and screens

5

2. Health

2.1 Basic Checks

IMNN does not have a ROIC to compare to the WACC, probably because it is not profitable.
IMNN has more shares outstanding than it did 1 year ago.
The number of shares outstanding for IMNN has been increased compared to 5 years ago.
There is no outstanding debt for IMNN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
IMNN Yearly Shares OutstandingIMNN Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2M 4M 6M 8M
IMNN Yearly Total Debt VS Total AssetsIMNN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M

2.2 Solvency

IMNN has an Altman-Z score of -62.63. This is a bad value and indicates that IMNN is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of IMNN (-62.63) is worse than 95.40% of its industry peers.
IMNN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -62.63
ROIC/WACCN/A
WACC29.46%
IMNN Yearly LT Debt VS Equity VS FCFIMNN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 20M -20M 40M

2.3 Liquidity

A Current Ratio of 1.51 indicates that IMNN should not have too much problems paying its short term obligations.
Looking at the Current ratio, with a value of 1.51, IMNN is doing worse than 82.48% of the companies in the same industry.
IMNN has a Quick Ratio of 1.51. This is a normal value and indicates that IMNN is financially healthy and should not expect problems in meeting its short term obligations.
The Quick ratio of IMNN (1.51) is worse than 81.42% of its industry peers.
Industry RankSector Rank
Current Ratio 1.51
Quick Ratio 1.51
IMNN Yearly Current Assets VS Current LiabilitesIMNN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M 50M

More info and screens

1

3. Growth

3.1 Past

IMNN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 42.20%, which is quite impressive.
The Revenue for IMNN has decreased by -100.00% in the past year. This is quite bad
EPS 1Y (TTM)42.2%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%8.11%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 13.21% on average over the next years. This is quite good.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y20.81%
EPS Next 2Y21.68%
EPS Next 3Y16.5%
EPS Next 5Y13.21%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
IMNN Yearly Revenue VS EstimatesIMNN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 200M 400M 600M 800M 1B
IMNN Yearly EPS VS EstimatesIMNN Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 -100 -200 -300

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

IMNN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year IMNN is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
IMNN Price Earnings VS Forward Price EarningsIMNN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
IMNN Per share dataIMNN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.5 -1 -1.5

4.3 Compensation for Growth

IMNN's earnings are expected to grow with 16.50% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y21.68%
EPS Next 3Y16.5%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for IMNN!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

IMUNON INC

NASDAQ:IMNN (1/21/2025, 8:07:26 PM)

Premarket: 0.8851 -0.01 (-1.27%)

0.8965

-0.02 (-1.82%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-07 2024-11-07/bmo
Earnings (Next)N/A N/A
Inst Owners11.06%
Inst Owner Change0%
Ins Owners0.97%
Ins Owner Change7.84%
Market Cap13.00M
Analysts82
Price Target13.46 (1401.39%)
Short Float %6.77%
Short Ratio3.15
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)9.01%
Min EPS beat(2)7.97%
Max EPS beat(2)10.04%
EPS beat(4)3
Avg EPS beat(4)9.68%
Min EPS beat(4)-24.34%
Max EPS beat(4)45.04%
EPS beat(8)4
Avg EPS beat(8)-4.7%
EPS beat(12)6
Avg EPS beat(12)-30.14%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)25.71%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0.25%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 3.47
P/tB 3.47
EV/EBITDA N/A
EPS(TTM)-1.89
EYN/A
EPS(NY)-1.13
Fwd EYN/A
FCF(TTM)-1.3
FCFYN/A
OCF(TTM)-1.28
OCFYN/A
SpS0
BVpS0.26
TBVpS0.26
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -186.58%
ROE -483.32%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-66.24%
ROA(5y)-59.99%
ROE(3y)-101.8%
ROE(5y)-107.31%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score1
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 3739.23%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.51
Quick Ratio 1.51
Altman-Z -62.63
F-Score1
WACC29.46%
ROIC/WACCN/A
Cap/Depr(3y)87.77%
Cap/Depr(5y)62.93%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)42.2%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%8.11%
EPS Next Y20.81%
EPS Next 2Y21.68%
EPS Next 3Y16.5%
EPS Next 5Y13.21%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y17.92%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y16.15%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y16.35%
OCF growth 3YN/A
OCF growth 5YN/A